Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 14/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716953 | 0.87 | POLQ (0.61) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL3741058 | 0.87 | POLQ (0.61) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL31589470 | 0.86 | POLQ (0.56) | POLQCES2DAO | |
| SCHEMBL14562998 | 0.86 | POLQ (0.56) | POLQCES2DAO | |
| SCHEMBL14263469 | 0.86 | POLQ (0.59) | POLQCES2DAOPTGDR2 | |
| SCHEMBL6864787 | 0.85 | CES2 (0.55) | POLQCES2RXRARXRBRXRG | |
| SCHEMBL1993639 | 0.80 | CES2 (0.52) | POLQCES2DAORXRARXRB | |
| SCHEMBL3278364 | 0.79 | CES2 (0.50) | POLQCES2DAORXRARXRB | |
| SCHEMBL4416164 | 0.79 | POLQ (0.51) | POLQCES2DAORXRARXRB | |
| SCHEMBL1538523 | 0.78 | DAO (0.49) | POLQCES2DAORXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916813-B2 | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1450901-A4 | (1-PHENYL-2-HETEROARYL)ETHYL-GUANIDINE COMPOUNDS AS INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE | BRISTOL MYERS SQUIBB CO (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6797842-B2 | BY ASYMMETRICALLY REDUCING AN OPTICALLY ACTIVE IMINE, USING A HYDRIDE REDUCING AGENT TO CONVERT TO AN OPTICALLY ACTIVE SECONDARY AMINE, WHICH THEN UNDERGOES HYDROGENOLYSIS; HIGH OPTICAL PURITY, SIMPLE, EFFICIENT | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1450901-A2 | (1-PHENYL-2-HETEROARYL)ETHYL-GUANIDINE COMPOUNDS AS INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE | Bristol-Myers Squibb Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040039033-A1 | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003050261-A2 | (1-PHENYL-2-HETEROARYL)ETHYL-GUANIDINE COMPOUNDS AS INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | POLQ 1835/4885CES2 2291/4885DAO 352/4885 |
| US-20040039033-A1 | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase | ATP5F1A, ATP5ME, ATP5F1D | POLQ 919/4885CES2 2404/4885DAO 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.